Top 5 Stocks to Buy Now
→ Elon Is Quietly Doubling Down on This Bizarre Asset (From Brownstone Research) (Ad)tc pixel Free CEROW Stock Alerts

CERo Therapeutics (CEROW) Competitors

$0.0015 0.00 (0.00%)
As of 06/23/2026
Compare

CEROW vs. SXTPW, DRTSW, APLMW, BIVIW, and CDIOW

Should you buy CERo Therapeutics stock or one of its competitors? MarketBeat compares CERo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CERo Therapeutics include 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Apollomics (APLMW), BioVie (BIVIW), and Cardio Diagnostics (CDIOW). These companies are all part of the "biotechnology" industry.

How does CERo Therapeutics compare to 60 Degrees Pharmaceuticals?

CERo Therapeutics (NASDAQ:CEROW) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than CERo Therapeutics. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for CERo Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 1.89 beat CERo Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
60 Degrees Pharmaceuticals Very Positive

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
60 Degrees Pharmaceuticals$1.00MN/AN/AN/AN/A

Summary

60 Degrees Pharmaceuticals beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to Alpha Tau Medical?

CERo Therapeutics (NASDAQ:CEROW) and Alpha Tau Medical (NASDAQ:DRTSW) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
Alpha Tau Medical N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
Alpha Tau MedicalN/AN/AN/AN/AN/A

In the previous week, Alpha Tau Medical had 3 more articles in the media than CERo Therapeutics. MarketBeat recorded 3 mentions for Alpha Tau Medical and 0 mentions for CERo Therapeutics. Alpha Tau Medical's average media sentiment score of 0.96 beat CERo Therapeutics' score of 0.00 indicating that Alpha Tau Medical is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
Alpha Tau Medical Positive

Summary

Alpha Tau Medical beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and CERo Therapeutics (NASDAQ:CEROW) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, risk, earnings and valuation.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
CERo TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Apollomics had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Apollomics and 0 mentions for CERo Therapeutics. Apollomics' average media sentiment score of 0.94 beat CERo Therapeutics' score of 0.00 indicating that Apollomics is being referred to more favorably in the media.

Company Overall Sentiment
Apollomics Positive
CERo Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
CERo Therapeutics N/A N/A N/A

Summary

Apollomics beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

How does CERo Therapeutics compare to BioVie?

CERo Therapeutics (NASDAQ:CEROW) and BioVie (NASDAQ:BIVIW) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, BioVie had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for BioVie and 0 mentions for CERo Therapeutics. BioVie's average media sentiment score of 0.94 beat CERo Therapeutics' score of 0.00 indicating that BioVie is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
BioVie Positive

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
BioVie N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
BioVieN/AN/AN/AN/AN/A

Summary

BioVie beats CERo Therapeutics on 2 of the 2 factors compared between the two stocks.

How does CERo Therapeutics compare to Cardio Diagnostics?

CERo Therapeutics (NASDAQ:CEROW) and Cardio Diagnostics (NASDAQ:CDIOW) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Company Net Margins Return on Equity Return on Assets
CERo TherapeuticsN/A N/A N/A
Cardio Diagnostics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CERo TherapeuticsN/AN/AN/AN/AN/A
Cardio Diagnostics$16.57KN/AN/AN/AN/A

In the previous week, Cardio Diagnostics had 2 more articles in the media than CERo Therapeutics. MarketBeat recorded 2 mentions for Cardio Diagnostics and 0 mentions for CERo Therapeutics. Cardio Diagnostics' average media sentiment score of 1.43 beat CERo Therapeutics' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company Overall Sentiment
CERo Therapeutics Neutral
Cardio Diagnostics Positive

Summary

Cardio Diagnostics beats CERo Therapeutics on 3 of the 3 factors compared between the two stocks.

Get CERo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CEROW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CEROW vs. The Competition

Export
MetricCERo TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$482.70M$6.61B$12.27B
Dividend YieldN/A3.86%2.67%5.89%
P/E RatioN/A3.1825.7623.97
Price / SalesN/A7,044.34553.2899.36
Price / CashN/A13.1346.3353.91
Price / BookN/A90.6210.706.32
Net IncomeN/A-$96.07M$3.57B$337.22M
7 Day PerformanceN/A1.86%0.79%-1.25%
1 Month PerformanceN/A0.64%0.22%-0.63%
1 Year PerformanceN/A71.08%30.84%27.95%

CERo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CEROW
CERo Therapeutics
N/A$0.00
flat		N/AN/A$0.00N/AN/A8
SXTPW
60 Degrees Pharmaceuticals
N/A$0.04
+5.6%		N/A-40.1%$0.00$1.00MN/A2
DRTSW
Alpha Tau Medical
N/A$1.98
+5.6%		N/A+913.3%$0.00N/AN/A80
APLMW
Apollomics
N/A$0.01
-0.8%		N/A-61.0%$0.00$8.50MN/A59
BIVIW
BioVie
N/A$0.33
-0.4%		N/AN/A$0.00N/AN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CEROW) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
SpaceX IPO “cancelled”?
SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...
InvestorPlace | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
The EPA just put a kill switch on Elon’s empire
A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...
Behind the Markets | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel